Dr Derek Grose
- Honorary Clinical Senior Lecturer (School of Cancer Sciences)
Publications
2024
Thapa, A. et al. (2024) The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland. Clinical Oncology, 36(5), pp. 287-299. (doi: 10.1016/j.clon.2024.02.004) (PMID:38395634)
2023
Hay, L. K., McLoone, P. , Borgaonkar, S., Schipani, S., Wilson, C., Grose, D., James, A. , Lamb, C. and Paterson, C. (2023) Can elderly patients be safely selected for head and neck radiotherapy without formal geriatric or frailty assessment: a retrospective cohort study. Clinical Otolaryngology, 48(2), pp. 240-244. (doi: 10.1111/coa.14005) (PMID:36366954)
Poon, W.-Y., Paterson, C., McLoone, P. , Grose, D., Schipani, S., Lamb, C., James, A. and Wilson, C. (2023) Survival outcomes in hypopharyngeal cancer in the West of Scotland Cancer Network. Clinical Otolaryngology, 48(2), pp. 235-239. (doi: 10.1111/coa.14003) (PMID:36344424)
2022
Zhou, S. et al. (2022) Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection. Oral Oncology, 128, 105870. (doi: 10.1016/j.oraloncology.2022.105870) (PMID:35447564)
2021
Jones, C. M. et al. (2021) Reply to comment on “The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic”. British Journal of Cancer, 124(3), pp. 679-680. (doi: 10.1038/s41416-020-01133-8) (PMID:33139799) (PMCID:PMC7851158)
Derby, S. , Forshaw, M., Lowrie, C., Grose, D., Marashi, H., McLoone, P. , Wilson, C. and McIntosh, D. (2021) Single modality radical radiotherapy is an acceptable alternative for the older patient with squamous cell carcinoma of the oesophagus. BMJ Open Gastroenterology, 8(1), e000492. (doi: 10.1136/bmjgast-2020-000492) (PMID:33504498) (PMCID:PMC7843319)
2020
Poon, W.-Y. et al. (2020) Comparative cohort study of volumetric modulated arc therapy for squamous cell cancer of unknown primary in the head and neck-involved neck only versus mucosal irradiation. Clinical Otolaryngology, 45(6), pp. 847-852. (doi: 10.1111/coa.13593) (PMID:32501648)
Jones, C. M. et al. (2020) Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. British Journal of Cancer, 123(5), pp. 709-713. (doi: 10.1038/s41416-020-0980-x) (PMID:32641867) (PMCID:PMC7341025)
Hay, L. K. et al. (2020) Analysis of dose using CBCT and synthetic CT during head and neck radiotherapy: A single centre feasibility study. Technical Innovations and Patient Support in Radiation Oncology, 14, pp. 21-29. (doi: 10.1016/j.tipsro.2020.02.004) (PMID:32226833) (PMCID:PMC7093804)
Sadler, K. A., Baxter, M.A., Peters, A.L. and Grose, D. (2020) Metastatic cutaneous deposits as the initial feature of rectal adenocarcinoma. Scottish Medical Journal, 65(1), pp. 28-31. (doi: 10.1177/0036933019897357) (PMID:31888409)
2019
Paterson, C. et al. (2019) Radiotherapy-induced xerostomia: a randomised, double-blind, controlled trial of Visco-ease™ oral spray compared with placebo in patients with cancer of the head and neck. British Journal of Oral and Maxillofacial Surgery, 57(10), pp. 1119-1125. (doi: 10.1016/j.bjoms.2019.10.300) (PMID:31672256)
2017
Grose, D. et al. (2017) The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 8(4), pp. 683-695. (doi: 10.21037/jgo.2017.04.01) (PMID:28890819) (PMCID:PMC5582039)
Paterson, C. et al. (2017) Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx: The MeRInO study. Clinical and Translational Radiation Oncology, 2, pp. 13-18. (doi: 10.1016/j.ctro.2016.12.003)
Articles
Thapa, A. et al. (2024) The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland. Clinical Oncology, 36(5), pp. 287-299. (doi: 10.1016/j.clon.2024.02.004) (PMID:38395634)
Hay, L. K., McLoone, P. , Borgaonkar, S., Schipani, S., Wilson, C., Grose, D., James, A. , Lamb, C. and Paterson, C. (2023) Can elderly patients be safely selected for head and neck radiotherapy without formal geriatric or frailty assessment: a retrospective cohort study. Clinical Otolaryngology, 48(2), pp. 240-244. (doi: 10.1111/coa.14005) (PMID:36366954)
Poon, W.-Y., Paterson, C., McLoone, P. , Grose, D., Schipani, S., Lamb, C., James, A. and Wilson, C. (2023) Survival outcomes in hypopharyngeal cancer in the West of Scotland Cancer Network. Clinical Otolaryngology, 48(2), pp. 235-239. (doi: 10.1111/coa.14003) (PMID:36344424)
Zhou, S. et al. (2022) Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection. Oral Oncology, 128, 105870. (doi: 10.1016/j.oraloncology.2022.105870) (PMID:35447564)
Jones, C. M. et al. (2021) Reply to comment on “The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic”. British Journal of Cancer, 124(3), pp. 679-680. (doi: 10.1038/s41416-020-01133-8) (PMID:33139799) (PMCID:PMC7851158)
Derby, S. , Forshaw, M., Lowrie, C., Grose, D., Marashi, H., McLoone, P. , Wilson, C. and McIntosh, D. (2021) Single modality radical radiotherapy is an acceptable alternative for the older patient with squamous cell carcinoma of the oesophagus. BMJ Open Gastroenterology, 8(1), e000492. (doi: 10.1136/bmjgast-2020-000492) (PMID:33504498) (PMCID:PMC7843319)
Poon, W.-Y. et al. (2020) Comparative cohort study of volumetric modulated arc therapy for squamous cell cancer of unknown primary in the head and neck-involved neck only versus mucosal irradiation. Clinical Otolaryngology, 45(6), pp. 847-852. (doi: 10.1111/coa.13593) (PMID:32501648)
Jones, C. M. et al. (2020) Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. British Journal of Cancer, 123(5), pp. 709-713. (doi: 10.1038/s41416-020-0980-x) (PMID:32641867) (PMCID:PMC7341025)
Hay, L. K. et al. (2020) Analysis of dose using CBCT and synthetic CT during head and neck radiotherapy: A single centre feasibility study. Technical Innovations and Patient Support in Radiation Oncology, 14, pp. 21-29. (doi: 10.1016/j.tipsro.2020.02.004) (PMID:32226833) (PMCID:PMC7093804)
Sadler, K. A., Baxter, M.A., Peters, A.L. and Grose, D. (2020) Metastatic cutaneous deposits as the initial feature of rectal adenocarcinoma. Scottish Medical Journal, 65(1), pp. 28-31. (doi: 10.1177/0036933019897357) (PMID:31888409)
Paterson, C. et al. (2019) Radiotherapy-induced xerostomia: a randomised, double-blind, controlled trial of Visco-ease™ oral spray compared with placebo in patients with cancer of the head and neck. British Journal of Oral and Maxillofacial Surgery, 57(10), pp. 1119-1125. (doi: 10.1016/j.bjoms.2019.10.300) (PMID:31672256)
Grose, D. et al. (2017) The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 8(4), pp. 683-695. (doi: 10.21037/jgo.2017.04.01) (PMID:28890819) (PMCID:PMC5582039)
Paterson, C. et al. (2017) Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx: The MeRInO study. Clinical and Translational Radiation Oncology, 2, pp. 13-18. (doi: 10.1016/j.ctro.2016.12.003)